Novel therapeutic targets for steatohepatitis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue , 2015, Pages S46-S50

  Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GALECTIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOPROTEIN GP 130; INFLAMMASOME; INTERLEUKIN 6; METFORMIN; PROTEIN LYSINE 6 OXIDASE; SODIUM GLUCOSE COTRANSPORTER; SOMATOMEDIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR;

ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; CLINICAL FEATURE; CYTOTOXICITY; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GENE MUTATION; GENETIC ANALYSIS; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; MEDICAL INFORMATION; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; SHORT SURVEY; GENETICS; INSULIN RESISTANCE; LIPOGENESIS; METABOLISM; PHYSIOLOGY;

CHEMOKINES; FATTY LIVER; FIBROBLAST GROWTH FACTORS; GALECTINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPOGENESIS; OXIDATIVE STRESS; PROTEIN-LYSINE 6-OXIDASE; RECEPTORS, CELL SURFACE;

EID: 84942819948     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.05.012     Document Type: Short Survey

References (22)

1. Pais R., Pascale A., Fedchuck L., Charlotte F., Poynard T., Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011, 35:23-28.
2. McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015, 62(5):1148-1155. [PubMed PMID: 25477264. Epub 2014/12/06]. 10.1016/j.jhep.2014.11.034.
3. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10:645-655.
4. Tian C., Stokowski R.P., Kershenobich D., Ballinger D.G., Hinds D.A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010, 42:21-23.
5. Chen Q.R., Braun R., Hu Y., et al. Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PloS One 2013, 8:e65982.
6. Nguyen T.A., Sanyal A.J. Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2012, 27(Suppl. 2):58-64.
7. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
8. Crabb D.W. Alcohol deranges hepatic lipid metabolism via altered transcriptional regulation. Trans Am Clin Climatol Assoc 2004, 115:273-287.
9. Argentou M., Tiniakos D.G., Karanikolas M., et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg 2009, 19:1313-1323.
10. Cariou B., Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Exp Opin Invest Drugs 2014, 23:1441-1448.
11. Harano Y., Yasui K., Toyama T., et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006, 26:613-620.
12. Jeong W.I., Osei-Hyiaman D., Park O., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008, 7:227-235.
13. Cheung O., Puri P., Eicken C., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
14. Cramp D.G. Lipid abnormalities in alcoholism. Contemp Issues Clin Biochem 1984, 1:149-160.
15. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
16. Puri P., Wiest M.M., Cheung O., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50:1827-1838.
17. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010, 362:1675-1685.
18. Mollace V., Sacco I., Janda E., et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011, 82:309-316.
19. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
20. Adams L.A., Zein C.O., Angulo P., Lindor K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368.
21. Wong C.C., Tse A.P., Huang Y.P., et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 2014, 60:1645-1658.
22. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385(9972):956-965. [PubMed PMID: 25468160. Epub 2014/12/04]. 10.1016/S0140-6736(14)61933-4.